Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, added to ongoing metformin therapy, were assessed in patients with type 2 diabetes who had inadequate glycemic control (HbA1c [A1C] ≥7 and ≤10%) with metformin alone. RESEARCH DESIGN AND METHODS—After a screening diet/exercise run-in period, a metformin dose titration/stabilization period, and a 2-week, single-blind, placebo run-in period, 701 patients, aged 19–78 years, with mild to moderate hyperglycemia (mean A1C 8.0%) receiving ongoing metformin (≥1,500 mg/day) were randomly assigned to receive the addition of placebo or sitagliptin 100 mg once-daily in a 1:2 ratio for 24 weeks. Patients exceeding specific glycemic limits were provided rescue therapy (pioglitazone) until the end of the study. The efficacy analyses were based on an all-patients-treated population using an ANCOVA and excluded data obtained after glycemic rescue. RESULTS—At week 24, sitagliptin treatment led to significant reductions compared with placebo in A1C (−0.65%), fasting plasma glucose, and 2-h postmeal glucose. Fasting insulin, fasting C-peptide, fasting proinsulin-to-insulin ratio, postmeal insulin and C-peptide areas under the curve (AUCs), postmeal insulin AUC–to–glucose AUC ratio, homeostasis model assessment of β-cell function, and quantitative insulin sensitivity check index were significantly improved with sitagliptin relative to placebo. A significantly greater proportion of patients achieved an A1C <7% with sitagliptin (47.0%) than with placebo (18.3%). There was no increased risk of hypoglycemia or gastrointestinal adverse experiences with sitagliptin compared with placebo. Body weight decreased similarly with sitagliptin and placebo. CONCLUSIONS—Sitagliptin 100 mg once-daily added to ongoing metformin therapy was efficacious and well tolerated in patients with type 2 diabetes who had inadequate glycemic control with metformin alone.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, studies report an increased incidence of nasopharyngitis in subjects randomly assigned to DPPIV inhibitor 35,38,40 ; in 1 study, 1 of 175 sitagliptin-treated subjects was hospitalized for angioedema.41”
From Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema (2008) · cites this paper as [40]
Citations
Cites
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065
Kim, D., Wang, L., Beconi, M., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0493156 · Cited by 822
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611
Standards of Medical Care for Patients With Diabetes Mellitus
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s33 · Cited by 609
HERMAN, G., STEVENS, C., VANDYCK, K., BERGMAN, A., YI, B., DESMET, M., SNYDER, K., HILLIARD, D., TANEN, M., & TANAKA, W. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.09.002 · Cited by 519
Herman, G. A., Bergman, A., Stevens, C., Kotey, P., Yi, B., Zhao, P., Dietrich, B., Golor, G., Schrodter, A., Keymeulen, B., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1009 · Cited by 495
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Pospisilik, J. A., Martin, J., Doty, T., Ehses, J. A., Pamir, N., Lynn, F. C., Piteau, S., Demuth, H.-U., McIntosh, C. H. S., & Pederson, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.741 · Cited by 332
Cited by
Items 601–700 of 785
Comparison of DPP-4 Inhibitors
Kim, N. H., & Kim, S. G. (2013) · Journal of Korean Diabetes · doi:10.4093/jkd.2013.14.3.111 · Cited by 3
Glucagon Like Peptides-1 Modulators as Newer Target for Diabetes
Vaidya, H. B., & Goyal, R. K. (2008) · Current Drug Targets · doi:10.2174/138945008785909284 · Cited by 3
Las incretinas como nuevas dianas terapéuticas de la diabetes tipo 2
Puig‐Domingo, M., & Reviriego, J. (2007) · Revista Clínica Española · doi:10.1157/13107949 · Cited by 4
The Incretin effect and the use of dipeptidyl peptidase IV inhibitors
Grant, P. S., & Dashora, U. K. (2007) · International Journal of Diabetes in Developing Countries · doi:10.4103/0973-3930.37038 · Cited by 4
Hanna, A., Woo, V. C., Yale, J., & Cooke, E. M. (2012) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2012.01.005 · Cited by 5
Management of type 2 diabetes: the GLP‐1 pathway
Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2008) · Future Prescriber · doi:10.1002/fps.39 · Cited by 3
Pharmacological control of blood sugar
Chatterjee, S., Davies, M. J., & Tarigopula, G. (2017) · Anaesthesia & intensive care medicine · doi:10.1016/j.mpaic.2017.06.017 · Cited by 3
Gliptin Therapies for Inhibiting Dipeptidyl Peptidase-4 in Type 2 Diabetes
Green, B. D., Bailey, C. J., & Flatt, P. R. (2010) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2010.06.02.19 · Cited by 4
Morin, N. P. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000003303 · Cited by 3
The incretin system in the management of type 2 diabetes mellitus
Stephens, J. W., Swansea, & Bain, S. C. (2010) · Clinical Medicine · doi:10.7861/clinmedicine.10-5-491 · Cited by 4
Singh, H., Rohilla, R., Jaswal, S., & Singla, M. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2290486 · Cited by 2
Peng, X., KLINGENSMITH, G. J., Hsia, D. S., Xie, Y., Czerniak, R., Tamborlane, W. V., & SHAH, A. S. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01700-3 · Cited by 2
Skyler, J. S. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1028-7_18 · Cited by 2
Tratamiento combinado de la diabetes mellitus tipo 2
Mata‐Cases, M. (2008) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/s1134-2072(08)70768-0 · Cited by 2
Otterbeck, P. E., & Banerji, M. A. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.6 · Cited by 1
Fang, H., Xu, F., Du, J., Li, L., Li, W., Shen, L., Wang, X., Xu, C., Bian, F., & Yi-ming, M. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13224 · Cited by 2
Ludvik, B. H., & Daniela, L. (2011) · Wiener klinische Wochenschrift · doi:10.1007/s00508-011-1559-6 · Cited by 3
Richard, J. W., & Raskin, P. (2011) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s5094 · Cited by 4
Palumbo, P. J., & Wert, J. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s8564 · Cited by 2
What Have We Learned About the Treatment of Type 2 Diabetes? The Evolving Paradigms
Freeman, J. S., & Horton, E. S. (2012) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31826fc5e5 · Cited by 2
Insulin, other hypoglycemic drugs, and glucagon
Page, R. C. (2010) · Side effects of drugs annual · doi:10.1016/s0378-6080(10)32042-3 · Cited by 2
Bode, B. W., & Amin, A. (2009) · Hospital Practice · doi:10.3810/hp.2009.12.249 · Cited by 2
Avances en el tratamiento de la diabetes mellitus tipo 2 y la enfermedad cardiovascular
Pi-Sunyer, X. (2008) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(08)73556-8 · Cited by 3
A taxi driver with type 2 diabetes
Brice, R. (2009) · BMJ · doi:10.1136/bmj.b1369 · Cited by 2
INCRETIN MIMETICS AND ENHANCERS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
Ruige, J. B. (2008) · Acta Clinica Belgica · doi:10.1179/acb.2008.63.2.004 · Cited by 2
Integrating incretin-based therapy into type 2 diabetes management.
Brunton, S. (2013) · PubMed · Cited by 3
Treatment Considerations for Diabetes: A Pharmacist’s Guide to Improving Care in the Elderly
Nicholas, A., Nadeau, D. A., & Johnson, A. C. L. (2009) · Journal of Pharmacy Practice · doi:10.1177/0897190009333160 · Cited by 2
Self-Monitoring of Blood Glucose in Glucagon-Like Peptide-1–Based Treatment Approaches
Schnell, O., & Felton, A.-M. (2013) · Diabetes Spectrum · doi:10.2337/diaspect.26.2.107 · Cited by 2
New treatments for type 2 diabetes in the UK – An evolving landscape
Barnett, A. H. (2010) · Primary care diabetes · doi:10.1016/j.pcd.2010.09.001 · Cited by 2
Tai, Y., Wu, C.-S., & Tsai, C. (2012) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2012.07.008 · Cited by 2
Ravasio, R. (2011) · Giornale Italiano di Health Technology Assessment · doi:10.1007/bf03320738 · Cited by 2
Sitagliptin in Patients with Non-Alcoholic Steatohepatitis: A Randomized, Placebo-Controlled Trial
Beaton, M. D., JOY, T. R., Tirona, R. G., Summers, K. L., Malhotra, N., & Chakrabarti, S. (2017) · Gastroenterology · doi:10.1016/s0016-5085(17)34002-7 · Cited by 2
Yu, M., Shankar, R. R., Zhang, R., Zhang, Y., Lin, J., O’Neill, E. A., Chen, G., Liu, S., Tu, Y., & Engel, S. S. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13517 · Cited by 2
Efecto en los niveles de colesterol total de la Sitagliptina en ratas con diabetes
Gallo, U. N. P. R., Vega, J. L. R., Moreno, H. M. S., de Chiclayo, U., Ishimine, R. G., Peruanas, U. A., Sánchez, C. W. A., & Gallo, U. N. P. R. (2020) · UCV HACER · doi:10.18050/revucvhacer.v9n3a1 · Cited by 2
Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes
Corsino, L., Cox, M. E., Rowell, J. V., & Green, J. B. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2109 · Cited by 2
Role of DPP-4 inhibitors in the management of type 2 diabetes
Ramesh, R., & Gupta, D. D. (2018) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20184872 · Cited by 5
A Short Review on Anti-diabetics for Uncontrolled Type 2 Diabetes Mellitus
Ahmad, H., & Chowdhury, M. A. N. (2019) · Medicine Today · doi:10.3329/medtoday.v31i2.41966 · Cited by 2
New developments in incretin‐based therapies: The current state of the field
Robertson, C. (2009) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2009.00453.x · Cited by 2
Valdez, C. A. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.7.650 · Cited by 2
Do we need new drugs for the treatment of type 2 diabetes mellitus?
Vervoort, G., & Tack, C. J. (2007) · PubMed · Cited by 2
VersorgungsLeitlinie, N. (2011) · Cited by 2
Dipeptidyl Peptidase 4 Inhibitors
Weber, A. E., & Thornberry, N. A. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc183.pub2 · Cited by 2
Medicinal chemistry and process development of the type 2 diabetes drug sitagliptin
Xu, J., & Liang, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27402-2.00019-x · Cited by 1
The Art and Science of Antidiabetic Medications and Obesity Management
Sawhney, S. K., Kapri, A., Chaudhary, G., & Chauhan, B. (2025) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575413887251001111806 · Cited by 1
70540 Henoch-Schönlein purpura induced by sitagliptin: a case report
Moschella, A., & Kirshen, C. (2025) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2026.04.973 · Cited by 1
Lund, N., Maslova, E., Chen, J., Giannini, J., Soro, M. B., Culligan, I., Richards, G., Taneja, L., Varghese, S., Li, Y., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-106299 · Cited by 2
Camuto, P., Guadagnini, D., Assalin, H. B., Magro, D. O., Santos, A., & Saad, M. J. A. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.06.010 · Cited by 1
Pharmacologic Approaches to Type 2 Diabetes and Obesity in Children and Adolescents
Pongsuwan, P. (2011) · Humana Press eBooks · doi:10.1007/978-1-60327-256-8_12 · Cited by 1
Le GLP-1 : de la physiologie À l’application thérapeutique
Choukem, S. P., & Gautier, J. (2007) · Cahiers de Nutrition et de Diététique · doi:10.1016/s0007-9960(07)91876-3 · Cited by 2
Retnakaran, R. R. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0552 · Cited by 1
Puech-Bret, N., & Gourdy, P. (2007) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(07)88657-3 · Cited by 1
Hypoglycemia associated with off-label sitagliptin use
Whitley, H. P., & Kelley, K. (2008) · International Medical Case Reports Journal · doi:10.2147/imcrj.s3962 · Cited by 1
Aye, M. M., & Jennings, P. (2009) · Practice Nursing · doi:10.12968/pnur.2009.20.4.41209 · Cited by 1
Hipoglucemia en pacientes diab?ticos tipo 2
Gonzlez, J. P. M., Prez, E. P., Martín-Oterino, J.-Á., & Cengoitiabengoa, M. B. (2008) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0211-3449(08)73228-4 · Cited by 2
Pharmacothérapie du diabète de type 2
Harper, W., CLEMENT, M. A., Goldenberg, R., Hanna, A., Main, A., Retnakaran, R. R., Sherifali, D., Woo, V. C., & Yale, J. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.006 · Cited by 1
Pharmacological control of blood sugar
Tarigopula, G., & Davies, M. J. (2014) · Anaesthesia & intensive care medicine · doi:10.1016/j.mpaic.2014.07.005 · Cited by 1
Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials
Doggrell, S. A. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.576671 · Cited by 1
Clinical Efficacy of Gliptins for Glycemic Control in Type 2 Diabeties Mellitus
Hayat, A. S., Shaikh, N., Ali, P. R., Shaikh, Z., & Khan, A. H. (2009) · Cited by 1
Advances in pharmacotherapy of Type 2 diabetes (Part-3: The gliptins)
Elhadd, T. A., Ghosh, S. K., Collier, A., & Sudan, K. (2010) · Cited by 1
Diagnosis, Evaluation, and Medical Management of Obesity and Diabetes
Chan, J. L., & Mantzoros, C. S. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-453-1_16 · Cited by 1
Bailey, T. S. (2011) · US Endocrinology · doi:10.17925/use.2011.07.02.82 · Cited by 1
Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapy
Gallwitz, B. (2008) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2008.04.00.40 · Cited by 1
Nazir, A., Sheikh, F. M., & Saleem, S. (2020) · The Professional Medical Journal · doi:10.29309/tpmj/2020.27.05.3940 · Cited by 1
Insulin, other hypoglycemic drugs, and glucagon
Page, R. C. L. (2008) · Side effects of drugs annual · doi:10.1016/s0378-6080(08)00042-1 · Cited by 2
Abrar, A., Khan, S., Rehman, M. U., Jan, T., & Faisal, M. (2013) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 1
Guisasola, F. Á. (2010) · Atención Primaria · doi:10.1016/s0212-6567(10)70006-8 · Cited by 3
Possible Protective Mechanisms of Sitagliptin against Isoproternol Induced Myocardial Injury in Rat
El‐Bakly, W. M. (2015) · Ain Shams Journal of Forensic Medicine and Clinical Toxicology · doi:10.21608/ajfm.2015.18653 · Cited by 1
Khan, A. M., Nowsherwan, N., Abbass, M., Ali, A., Afridi, H., Gul, W., & Zaib, S. (2021) · American Journal of Health Medicine and Nursing Practice · doi:10.47672/ajhmn.863 · Cited by 1
Insulin, other hypoglycemic drugs, and glucagon
Page, R. C. L. (2009) · Side effects of drugs annual · doi:10.1016/s0378-6080(09)03142-0 · Cited by 2
Gautier, J., & Choukem, S. P. (2008) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2008.04.009 · Cited by 15
Kelesidis, T., Kelesidis, I., & Mantzoros, C. S. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-453-1_3 · Cited by 1
The role of incretin‐based therapies in the management of type 2 diabetes
Russell-Jones, D. L. (2009) · Practical Diabetes · doi:10.1002/pdi.1368 · Cited by 1
Impaired glucose tolerance and incretins in chronic liver disease
Gorrell, M. D. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05268.x · Cited by 1
Vilsbøll, T. (2007) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.3.1.13 · Cited by 2
Incretin-based therapies and their future in Type 2 diabetes mellitus
Sonnett, T. E., Robinson, J. D., & Bowen, K. A. (2011) · Therapy · doi:10.2217/thy.11.4 · Cited by 1
Dipeptidyl Peptidase 4 Inhibitors
Weber, A. E., & Thornberry, N. A. (2010) · Wiley eBooks · doi:10.1002/0471266949.bmc183 · Cited by 2
How incretin-based therapies address the spectrum of physiologic disturbance in type 2 diabetes
(2010) · The Internet Journal of Academic Physician Assistants · doi:10.5580/172c · Cited by 1
The physiological effects of resistant starch on obesity and diabetes
Goldsmith, F. (2014) · Louisiana State University · doi:10.31390/gradschool_dissertations.3983 · Cited by 2
Zilli, R. W. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2017.tde-16112017-084026 · Cited by 1
Exploring the structure, function & regulation of the human glucagon-like peptide-1 receptor
Huang, Y. (2011) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 2
(2007) · Endocrine Practice · doi:10.1016/s1530-891x(20)46423-7 · Cited by 1
Consensus ADA/EASD 2009 : l’algorithme pour le traitement médical du diabète de type 2 est utile !
Sauvanet, J.-P. (2010) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(10)70035-3 · Cited by 3
How to use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies
Aloi, J., & McCall, A. L. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch31
Athanasia, K., Marina, S., & Stavros, I. (2011) · InTech eBooks · doi:10.5772/20616
Is there a Role for Incretin‐Based Therapy in Combination with Insulin?
Sathananthan, M., & Vella, A. V. (2011) · Wiley eBooks · doi:10.1002/9781444340280.ch10
Nogueira, K. C. (2012) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2012.tde-27072012-155318
Types of Diabetes that the Dipeptidyl Peptidase-4 Inhibitor May Act Effectively and Safely
Yanai, H. (2011) · The Open Diabetes Journal · doi:10.2174/1876524601104010001
Advances in the Treatment of Type 2 Diabetes and Cardiovascular Disease
Pi-Sunyer, X. (2008) · Revista Española de Cardiología
Therapie des Diabetes mellitus Typ 2 und kardiovaskuläre Komplikationen: Was ist evidenzbasiert?
Tiburcy, M., & Zimmermann, W. (2008) · Der Kardiologe · doi:10.1007/s12181-008-0119-4
Prise en charge thérapeutique du diabète de type 2
Halbron, M. (2009) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(09)49754-0 · Cited by 1
La sitagliptine, inhibiteur de la DPP-IV : un nouvel anti-diabétique oral
Mohammedi, K., Olivier, S., & Roussel, R. (2008) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(08)70425-5
Improving Insulin Sensitivity: A Review of New Therapies
Rhee, M. K., & Umpierrez, G. E. (2008) · Clinical cornerstone · doi:10.1016/s1098-3597(09)60023-5 · Cited by 1
Sitagliptin and metformin combination therapy for the treatment of Type 2 diabetes
Gallwitz, B. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.23 · Cited by 1
Raz, I. (2007) · Drugs · doi:10.2165/00003495-200767040-00008
Tratamiento de la diabetes de tipo 2
Halbron, M. (2010) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(10)70518-3
Prise de poids et traitements antidiabétiques
Vergès, B. L. (2008) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(08)74896-x · Cited by 1
The backbone of oral glucose‐lowering therapy: time for a paradigm shift?
Seufert, J. (2009) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2009.00676.x
Krentz, A. J., Heinemann, L., & Hompesch, M. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4920-0_2
Gestione terapeutica del diabete di tipo 2
Halbron, M. (2010) · EMC - AKOS - Trattato di Medicina · doi:10.1016/s1634-7358(10)70317-x
Managing diabetes with new pharmaceutical agents
Gopalappa, J., & Jennings, P. E. (2010) · Practice Nursing · doi:10.12968/pnur.2010.21.12.634
Metadata
- Authors
- Charbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group
- Affiliations
- Centre Hospitalier Universitaire de Nantes (FR)
- Sheba Medical Center (IL)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-12-01
- Volume
- 29
- Issue
- 12
- Pages
- 2638-2643
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2171512247
- Cited by
- 790
- References
- 12
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 7 · 2023: 9 · 2022: 10 · 2021: 19 · 2020: 19 · 2019: 15 · 2018: 12 · 2017: 27 · 2016: 29 · 2015: 39 · 2014: 47 · 2013: 48 · 2012: 47
- FWCI
- 60.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- sitagliptin, DPP-4 inhibitors, metformin, type 2 diabetes, inadequate glycemic control, HbA1c, pioglitazone, insulin sensitivity, beta-cell function, hypoglycemia, gastrointestinal adverse effects, body weight
- MeSH terms
- Sitagliptin Phosphate, Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Glycoproteins, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Placebos, Proinsulin, Protease Inhibitors, Pyrazines, Triazoles, Single-Blind Method, Dipeptidyl Peptidase 4, Dipeptidyl-Peptidase IV Inhibitors, Adenosine Deaminase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.